Email this article The clinical efficiency and safety of iodide-bromine balneotherapy in patients with coronary heart disease concurrent with chronic obstructive pulmonary disease
- Authors: Zunnunov Z.R.1, Zunnunov ZR2
-
Affiliations:
- Филиал НИИ терапии и медицинской реабилитации
- Branch of the Research Institute of Therapy and Medical Rehabilitation
- Issue: Vol 82, No 1 (2010)
- Pages: 24-27
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33373
- ID: 33373
Cite item
Full Text
Abstract
Aim: to evaluate the efficiency of iodide-bromine balneotherapy (IBB) in patients with coronary heart disease (CHD) concurrent with chronic obstructive pulmonary disease (COPD).
Subjects and methods. Sixty-six patients with CHD, Functional Class II stable angina on exertion concurrent with mild and moderate COPD were examined. Group 1 included 36 patients with CHD concurrent with mild and moderate COPD (a study group); Group 2 consisted of 30 patients (a control group). The groups were matched for age, gender, and concomitant abnormality. The patients from both groups undergone a complex clinical and instrumental study (clinical and biochemical study, echocardiography, 24-hour ECG monitoring, EchoCG, external respiration function (ERF) test. In both groups, CHD and COPD were treated by the generally accepted standards, Group 1 patients were additionally given IBB at a water temperature of 37°C; the concentration of iodine and bromine was 10-15 and 30-40 m/l, respectively; the duration was 10-15 min for 2 consecutive days, followed by a rest day or every second day; the course comprised 10-12 sessions.
Results. After the course of IBB, there were significant reductions in the number of anginal attacks and the dose of nitrates weekly, the number of episodes of supraventricular and ventricular premature contractions, producing no impact on the cardiac conduction system. The duration of silent myocardial ischemia and the degree of ST-segment depression significantly reduced. No significant changes were obtained in the control group. ERF examination confirmed the safety of IBB used in patients with CHD and COPD.
Conclusion. IBB has a beneficial antiischemic activity in patients with CHD concurrent with COPD, without producing a negative impact on ERF.
Subjects and methods. Sixty-six patients with CHD, Functional Class II stable angina on exertion concurrent with mild and moderate COPD were examined. Group 1 included 36 patients with CHD concurrent with mild and moderate COPD (a study group); Group 2 consisted of 30 patients (a control group). The groups were matched for age, gender, and concomitant abnormality. The patients from both groups undergone a complex clinical and instrumental study (clinical and biochemical study, echocardiography, 24-hour ECG monitoring, EchoCG, external respiration function (ERF) test. In both groups, CHD and COPD were treated by the generally accepted standards, Group 1 patients were additionally given IBB at a water temperature of 37°C; the concentration of iodine and bromine was 10-15 and 30-40 m/l, respectively; the duration was 10-15 min for 2 consecutive days, followed by a rest day or every second day; the course comprised 10-12 sessions.
Results. After the course of IBB, there were significant reductions in the number of anginal attacks and the dose of nitrates weekly, the number of episodes of supraventricular and ventricular premature contractions, producing no impact on the cardiac conduction system. The duration of silent myocardial ischemia and the degree of ST-segment depression significantly reduced. No significant changes were obtained in the control group. ERF examination confirmed the safety of IBB used in patients with CHD and COPD.
Conclusion. IBB has a beneficial antiischemic activity in patients with CHD concurrent with COPD, without producing a negative impact on ERF.
About the authors
Zokirzhan Ruzievich Zunnunov
Филиал НИИ терапии и медицинской реабилитации
Email: zzokirjon@mail.ru
д-р мед. наук, проф., директор Термезского филиала НИИ терапии и медицинской реабилитации; Филиал НИИ терапии и медицинской реабилитации
Z R Zunnunov
Branch of the Research Institute of Therapy and Medical RehabilitationBranch of the Research Institute of Therapy and Medical Rehabilitation
References
- Dankner R., Gjldbourt U., Boyko V. et al. Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease: BIP Study Group. Am. J. Gardiol. 2003; 91: 121-127.
- Behar S., Panosh A., Keicher-Reiss H. Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction. SPRINT Study Group. Am. J. Med. 1992; 93 (6): 637-641.
- American Heart Association. Heart disease and stroke statistics - 2005. Update. Dallas, Texas: American Heart Association; 2005.
- Карпов Р. С., Дудко В. А., Кляшев С. М. Сердце - легкие: патогенез, клиника, функциональная диагностика и лечение сочетанных форм ишемической болезни сердца и хронических обструктивных болезней легких. Томск: STT; 2004.
- Задионченко B. C., Кузьмичева Н. В., Свиридов А. А. и др. Клинико-функциональные особенности артериальной гипертонии при хроническом бронхообструктивном синдроме. Тер. арх. 2000; 1: 35-37.
- Козлова Л. И., Бузинов Р. В., Чучалин А. Г. Хронические обструктивные болезни легких у больных с ишемической болезнью сердца: 15-летнее наблюдение. Тер. арх. 2001; 3: 27-32.
- Гроссу А. А., Штырбул А. А., Шевченко Н. М. Нарушение сердечного ритма у больных с хроническими обструктивными заболеваниями легких. Тер. арх. 1977; 12: 133-136.
- Kaplan N. M. Multiple rick factors for coronary heart disease in patient with hypertension. J. Hypertens. 1995; 1 (2): 1-2.
- Авдеев С. Н., Царева Н. А., Чучалин А. Г. Лечение легочной гипертензии при хронической обструктивной болезни легких. Сердеч. недостат. 2002; 3: 144-148.
- Доценко Я. И., Должецкий З. К., Амлинский М. В. и др. Особенности течения ишемической болезни сердца на фоне хронических заболеваний легких. В кн.: Новые направления в диагностике и лечении болезней сердца. М.; 1983: 54-55.
- Коломец Н. М., Бакшеев В. Н., Зарубина Е. Г. Клиническая эффективность ивабрадина у пациентов с ишемической болезнью сердца в сочетании с хронической обструктивной болезнью легких. Кардиология 2008; 3: 13-19.
- Shattock M., Camm A. J. Pure heart rate reduction: The if channels from discovery therapeutic target. Br. J. Cardiol. 2006; 13 (1): 27-35.
- Diaz A., Bourassa M. G., Guertin M. G., Tardif J. G. Long-term prognostic value of resting heart rate in patients with suspected of proven coronary artery disease. Eur. Heart. J. 2005; 26: 967-974.
- Замотаев Ю. Н., Косов В. А., Гулеватый Г. В. Реабилитация больных ИБС, перенесших коронарное шунтирование на санаторном этапе с использованием методов комплексной физиотерапии. Вопр. курортол. 2007; 5: 8-12.
- Айропетова Н. С., Поликанова Е. Б., Давыдова О. Б. и др. Применение скипидарных ванн в восстановительном лечении больных ХОБЛ. Вопр. курортол. 2007; 4: 17-22.
- Виноградов В. Н., Кандрикина Т. А. Влияние йодобромных ванн на состояние центральной гемодинамики у больных гипертонической болезнью и ишемической болезнью сердца. Вопр. курортол. 1990; 4: 15-18.
Supplementary files
